Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies.
Home
Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies.
Free Netflix and Sky TV trial deal ends in hours – here’s how to claim it
Private sector grows steadily in May amid signs of cooling services inflation
Net migration to UK drops after hitting record levels, fuelling election debate
Ten Hag saves United career or City win double? – FA Cup final talking points
This will close in 0 seconds